High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation

Basit Öğe Kaydı
dc.contributor.authorHazar, V
dc.contributor.authorKansoy, S
dc.contributor.authorKupesiz, A
dc.contributor.authorAksoylar, S
dc.contributor.authorKantar, M
dc.contributor.authorYesilipek, A
dc.date.accessioned2019-10-27T19:03:48Z
dc.date.available2019-10-27T19:03:48Z
dc.date.issued2004
dc.departmentEge Üniversitesien_US
dc.description.abstractCytomegalovirus (CMV) disease remains an important cause of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). We evaluated high-dose acyclovir (HDACV) and pre-emptive ganciclovir to prevent CMV disease in 76 children who underwent peripheral blood stem cell transplantation (PBSCT) and were at risk for CMV reactivation and disease ( both recipient and donor seropositive) from May 1998 to April 2003. All received HDACV from day - 9 to 6 months post transplant in conjunction with weekly CMV pp65 antigenemia monitoring. The incidence of antigenemia in this cohort was 19.7%, at a median of 22 days post-PBSCT. The frequencies were 26.4 and 4.4% in allogeneic and autologous groups, respectively ( P = 0.03). Patients with nonmalignant disease had higher CMV antigenemia than those with malignant disease (30.8 vs 8.1%, P = 0.02). Age at PBSCT, sex, graft-versus-host disease (GVHD) prophylaxis regimen and presence of acute GVHD did not affect the risk of CMV antigenemia. No ne of the patients who had positive pp65 antigenemia developed CMV disease during the study period. We conclude that pp65 anti-genemia-guided HDACV and pre-emptive ganciclovir may prevent CMV disease in children undergoing PBSCT.en_US
dc.identifier.doi10.1038/sj.bmt.1704463en_US
dc.identifier.endpage935en_US
dc.identifier.issn0268-3369
dc.identifier.issue9en_US
dc.identifier.pmid15034541en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage931en_US
dc.identifier.urihttps://doi.org/10.1038/sj.bmt.1704463
dc.identifier.urihttps://hdl.handle.net/11454/38152
dc.identifier.volume33en_US
dc.identifier.wosWOS:000220951700008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherNature Publishing Groupen_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectcytomegalovirusen_US
dc.subjecthigh-dose acycloviren_US
dc.subjectpp-65 antigenemiaen_US
dc.subjectperipheral blood stem cell transplantationen_US
dc.subjectchildrenen_US
dc.titleHigh-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu